Sachin Kamal-Bahl, PhD, is Vice President and Head of the Global Health and Value Innovation Center at Pfizer, a newly created center under his leadership, that develops and integrates innovative approaches based on well-considered risks and strong technical underpinnings to address the access, pricing, or valuation challenges and opportunities facing the pharmaceutical industry. Under Sachin’s leadership and vision, the Center has been accelerating the pipeline of approaches to solve for the environmental challenges – examples of which range from leveraging joint EMA/HTA advice pathways, EMA adaptive licensing approaches, and systematic patient engagement in order to optimize drug development planning and access at launch to identifying innovative pricing and financing solutions for new drugs including those for curative treatments such as gene therapies in order to address payer concerns about prices and budget impact. Prior to coming to Pfizer in 2014, Sachin held various leadership positions in market access, pricing, and health economics and outcomes research at Merck & Co. In addition to leading the Innovation Center, Sachin holds adjunct appointments at two academic institutions, the University of Pennsylvania’s Leonard Davis Institute of Health Economics and the University of Maryland’s School of Pharmacy; serves on advisory boards of initiatives led by professional societies/organizations; and is a frequently invited speaker at external conferences.

Recent Posts by Sachin Kamal-Bahl

Should Value Frameworks Take A ‘Societal Perspective’?

While compelling arguments exist for value frameworks to assume a societal perspective, in practice it is challenging for them to do so.

Strategies To Address The Challenges Of Outcomes-Based Pricing Agreements For Pharmaceuticals

Outcomes-based pricing agreements may both improve access to treatments for patients who derive the greatest benefits from them and strengthen pharmaceutical companies’, clinicians’, and insurers’ interest in discouraging the use of ineffective therapies. However, stakeholders are missing...

Family Spillover Effects For Health Care Treatments Should Be Valued

Measuring caregiver burden to calculate the societal cost of disease is important. However, it is arguably far less important than the direct loss in wellbeing to families and others who have a loved one afflicted with disease.